(23.09.2023) "The integration of our global network of sites is progressing well, delivering operational benefits that enhance our ability to meetdiverse client needs and accelerate project timelines." Read More
(18.09.2024) The new identity reflects OXB’s unique combination of technical excellence, innovation and unwavering commitment to deliver consistent high quality at every stage of viral vector development and manufacturing. Read More
(02.09.2024) Lucinda Crabtree was previously at MorphoSys AG where she served as CFO, leading a finance team across the US and Germany until the company’s acquisition by Novartis. Read More
(27.09.2024) On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar on its adeno-associated virus (AAV) Read More
(08.08.2024) Oxford Biomedica has continued to see strong momentum in 2024 with revenues for the first half expected to be approximately £50 million. As previously communicated, revenues are expected Read More
(25.07.2024) Ms. Espinasse brings more than two decades of experience across the legal and healthcare sectors and since 2021 has served as the General Counsel and Compliance Officer at Read More
(17.07.2024) Lucinda Crabtree was previously CFO at MorphoSys AG. As CFO of MorphoSys, Lucy led a finance team across the US and Germany until the closing of the acquisition of the company by Novartis. Read More
(29.04.2024) Chief Executive Officer Dr. Frank Mathias, one year into his role, is successfully leading the transformation of Oxford Biomedica into a global, pure-play, quality and innovation-led cell and gene therapy CDMO Read More
(20.03.2024) Year to date, Oxford Biomedica has experienced consistently strong demand for its CDMO services across all key viral vector types, with its portfolio of client programmes transitioning towards later stage work. Read More
(11.03.2024) Peter Soelkner has more than 30 years’ experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma Read More
(05.03.2024) In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately £90 million. Operating EBITDA loss for Read More
(29.01.2024) The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica's position as a world-leading cell and gene therapy CDMO. This strategic move broadens the Company's international Read More